Medpace Holdings, Inc. $MEDP Shares Sold by EntryPoint Capital LLC

Key Points

• EntryPoint Capital LLC reduced its holdings in Medpace Holdings, Inc. by 43.4%, selling 653 shares and bringing its total to 850 shares valued at approximately $259,000.
• Several institutional investors, including Brooklyn Investment Group and Whittier Trust Co., have increased their stakes in Medpace, with Brooklyn's stake rising by 244.8%.
• Medpace reported an EPS of $3.10 for the recent quarter, surpassing the consensus estimate, while its quarterly revenue grew by 14.2% year-over-year.

EntryPoint Capital LLC lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 43.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 850 shares of the company's stock after selling 653 shares during the period. EntryPoint Capital LLC's holdings in Medpace were worth $259,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the business. Invesco Ltd. boosted its holdings in Medpace by 9.4% in the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock worth $361,596,000 after acquiring an additional 102,015 shares in the last quarter. Mawer Investment Management Ltd. acquired a new stake in Medpace in the first quarter worth about $212,131,000. Bessemer Group Inc. boosted its holdings in Medpace by 1.1% in the first quarter. Bessemer Group Inc. now owns 582,269 shares of the company's stock worth $177,411,000 after acquiring an additional 6,225 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Medpace by 31.3% in the fourth quarter. AQR Capital Management LLC now owns 480,186 shares of the company's stock worth $159,532,000 after acquiring an additional 114,436 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in Medpace by 36.0% in the first quarter. Northern Trust Corp now owns 337,489 shares of the company's stock worth $102,830,000 after acquiring an additional 89,347 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Trading Up 0.5%

Medpace stock traded up $2.49 during mid-day trading on Tuesday, hitting $469.29. The company had a trading volume of 238,987 shares, compared to its average volume of 451,360. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $501.30. The company's fifty day moving average is $382.18 and its 200-day moving average is $335.65. The company has a market capitalization of $13.18 billion, a price-to-earnings ratio of 34.89, a P/E/G ratio of 2.92 and a beta of 1.42.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. During the same quarter in the prior year, the firm posted $2.75 EPS. The business's quarterly revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several research reports. Cowen downgraded Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. UBS Group downgraded Medpace from a "neutral" rating to a "sell" rating and upped their target price for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th. Truist Financial upped their target price on Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. Robert W. Baird lifted their target price on Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Reduce" and a consensus price target of $406.60.

Insiders Place Their Bets

In other Medpace news, CFO Kevin M. Brady sold 12,000 shares of the company's stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the sale, the chief financial officer owned 6,000 shares in the company, valued at approximately $2,725,380. This represents a 66.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the company's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the sale, the general counsel owned 10,343 shares in the company, valued at approximately $4,654,350. This represents a 22.48% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 114,450 shares of company stock worth $51,791,251. Corporate insiders own 20.30% of the company's stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.